Table 4 First-line immunochemotherapy for marginal zone lymphoma

Salar et al. [19]

R-fludarabine

Any stage MALT lymphoma

II

22

100% (62 + 38)

2-year, 88%

2-year, 100%

Zucca et al. [23, 25]

R–Cb

Any stage MALT lymphoma

III (R–Cb vs R vs Cb)

132 (total 401)

94.7% (78.8 + 15.9)

5-year, 68%^a

5-year, 90%

Kang et al. [24]

R–CVP

Stage III/IV MZL

II

41

87.5% (60 + 27.5)

3-year, 59%

3-year, 94%

Salar et al. [26, 27]

R–B

Any stage MALT lymphoma

II

57

100%

7-year, 92.8%

7-year, 94.7%

Oh (present study)

R–CVP followed by R-maintenance

Stage III/IV MZL

II

45

–

3-year, 81%

3-year, 90%